Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UniCAR02-T-pPSMA in Advanced Prostate Cancer
NCT04633148Phase 1Terminated
- Sponsor
- AvenCell Therapeutics
- Start
- Nov 2020
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UniCAR02-T-pPSMA in prostate cancer (PCa), sponsored by AvenCell Therapeutics. Primary endpoints: Safety and tolerability, Incidence of dose limiting toxicity and 1 more. Started Nov 2020; status: terminated.
02
Drugs
UniCAR02-T-pPSMA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04633148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633148.